Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.

Bonanad-Lozano, Clara; García Blas, Sergio; Amat-Santos, Ignacio; Gonzalez-Manzanares, Rafael; Sanchís, Juan; López Otero, Diego; Nombela Franco, Luis; Gheorge, Livia; Sanz-Sánchez, Jorge; Baladrón Zorita, Carlos; Iñiguez Romo, Andrés; Muñoz García, Antonio Jesús; Vilalta, Victoria; Ojeda, Soledad; Veiga Fernández, Gabriela; Córdoba Soriano, Juan Gabriel; Cepas, Pedro; Sandín Rollán, Miriam; Ríos, Xacobe Flores; Palma-Carbajal, Ricardo; Martín Reyes, Roberto; Romaguera, Rafael; Avanzas, Pablo; Franco-Peláez, Juan A; Martín Moreiras, Javier; Gonzalez Juanatey, José Ramón; Tirado, Gabriela; Calle, German; Díez, José Luis; Santos-Martínez, Sandra; Domínguez Erquicia, Pablo; García, Erika Muños; Fernandez-Nofrerias, Eduard; López País, Javier; Gonzalo, Nieves; Barri, Alejandro Gutierrez; Asmarats, Lluis; López Pérez, Manuel; Domínguez Rodríguez, Luis Manuel; Cobo, Marta; González Bermúdez, Inmaculada; García Álvarez, Ana; García Pavía, Pablo; Fuster, Valentín; Ibáñez, Borja; Raposeiras-Roubín, Sergio

Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.

Patients with aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) experience a great improvement in health status. Dapagliflozin has been shown to reduce death and heart failure (HF) in these patients. However, the impact of dapagliflozin on improving health status after TAVI...

Descripción completa

Detalles Bibliográficos
Autores:	Bonanad-Lozano, Clara, García Blas, Sergio, Amat-Santos, Ignacio, Gonzalez-Manzanares, Rafael, Sanchís, Juan, López Otero, Diego, Nombela Franco, Luis, Gheorge, Livia, Sanz-Sánchez, Jorge, Baladrón Zorita, Carlos, Iñiguez Romo, Andrés, Muñoz García, Antonio Jesús, Vilalta, Victoria, Ojeda, Soledad, Veiga Fernández, Gabriela, Córdoba Soriano, Juan Gabriel, Cepas, Pedro, Sandín Rollán, Miriam, Ríos, Xacobe Flores, Palma-Carbajal, Ricardo, Martín Reyes, Roberto, Romaguera, Rafael, Avanzas, Pablo, Franco-Peláez, Juan A, Martín Moreiras, Javier, Gonzalez Juanatey, José Ramón, Tirado, Gabriela, Calle, German, Díez, José Luis, Santos-Martínez, Sandra, Domínguez Erquicia, Pablo, García, Erika Muños, Fernandez-Nofrerias, Eduard, López País, Javier, Gonzalo, Nieves, Barri, Alejandro Gutierrez, Asmarats, Lluis, López Pérez, Manuel, Domínguez Rodríguez, Luis Manuel, Cobo, Marta, González Bermúdez, Inmaculada, García Álvarez, Ana, García Pavía, Pablo, Fuster, Valentín, Ibáñez, Borja, Raposeiras-Roubín, Sergio
Tipo de recurso:	artículo
Fecha de publicación:	2025
País:	España
Institución:	Instituto de Salud Carlos III (ISCIII)
Repositorio:	Repisalud
Idioma:	inglés
OAI Identifier:	oai:repisalud.isciii.es:20.500.12105/27044
Acceso en línea:	https://hdl.handle.net/20.500.12105/27044
Access Level:	acceso abierto
Palabra clave:	NYHA functional class aortic stenosis dapagliflozin quality of life transcatheter aortic valve implantation (TAVI)

id	ES_1ddaa2ddb52f75b8a2183542e0c3e11d
oai_identifier_str	oai:repisalud.isciii.es:20.500.12105/27044
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.Bonanad-Lozano, ClaraGarcía Blas, SergioAmat-Santos, IgnacioGonzalez-Manzanares, RafaelSanchís, JuanLópez Otero, DiegoNombela Franco, LuisGheorge, LiviaSanz-Sánchez, JorgeBaladrón Zorita, CarlosIñiguez Romo, AndrésMuñoz García, Antonio JesúsVilalta, VictoriaOjeda, SoledadVeiga Fernández, GabrielaCórdoba Soriano, Juan GabrielCepas, PedroSandín Rollán, MiriamRíos, Xacobe FloresPalma-Carbajal, RicardoMartín Reyes, RobertoRomaguera, RafaelAvanzas, PabloFranco-Peláez, Juan AMartín Moreiras, JavierGonzalez Juanatey, José RamónTirado, GabrielaCalle, GermanDíez, José LuisSantos-Martínez, SandraDomínguez Erquicia, PabloGarcía, Erika MuñosFernandez-Nofrerias, EduardLópez País, JavierGonzalo, NievesBarri, Alejandro GutierrezAsmarats, LluisLópez Pérez, ManuelDomínguez Rodríguez, Luis ManuelCobo, MartaGonzález Bermúdez, InmaculadaGarcía Álvarez, AnaGarcía Pavía, PabloFuster, ValentínIbáñez, BorjaRaposeiras-Roubín, SergioNYHA functional classaortic stenosisdapagliflozinquality of lifetranscatheter aortic valve implantation (TAVI)Patients with aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) experience a great improvement in health status. Dapagliflozin has been shown to reduce death and heart failure (HF) in these patients. However, the impact of dapagliflozin on improving health status after TAVI is unknown. In this prespecified analysis of the DapaTAVI (Dapagliflozin After Transcatheter Aortic Valve Implantation) trial, we examined the effects of dapagliflozin on health status by using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The DapaTAVI trial randomized patients undergoing TAVI to receive or not receive dapagliflozin. We assessed the change in KCCQ score from baseline to 3 and 12 months by using an ordinal logistic regression model. Additionally, we analyzed the effect of dapagliflozin on the composite of death or worsening HF by baseline KCCQ score. A total of 964 patients had baseline KCCQ scores (mean 39.5 ± 22.2). Patients in both arms of the study exhibited improvements in KCCQ score, without significant differences between groups in the change in KCCQ score at 3 or 12 months (3-month OR for improvement: 0.96; 95% CI: 0.72-1.26; P = 0.745; 12-month OR: 1.03; 95% CI: 0.83-1.27; P = 0.819). At 12 months, similar proportions of patients in the dapagliflozin and control groups showed clinically meaningful improvements, with 43.4% vs 45.4%, respectively, improving by >50 points. The clinical benefits of dapagliflozin after TAVI appeared to be similar across the full range of baseline KCCQ scores. TAVI was associated with a substantial improvement in KCCQ scores. However, the addition of dapagliflozin following the procedure did not confer an additional benefit in health status compared with standard care. (Dapagliflozin After Transcatheter Aortic Valve Implantation [DapaTAVI]; NCT04696185).ELSEVIER20252025-12-1620252025-10-1420252025-10-14research articlehttp://purl.org/coar/resource_type/c_2df8fbb1AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/27044reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/270442026-06-12T12:43:37Z
dc.title.none.fl_str_mv	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
title	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
spellingShingle	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. Bonanad-Lozano, Clara NYHA functional class aortic stenosis dapagliflozin quality of life transcatheter aortic valve implantation (TAVI)
title_short	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
title_full	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
title_fullStr	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
title_full_unstemmed	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
title_sort	Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
dc.creator.none.fl_str_mv	Bonanad-Lozano, Clara García Blas, Sergio Amat-Santos, Ignacio Gonzalez-Manzanares, Rafael Sanchís, Juan López Otero, Diego Nombela Franco, Luis Gheorge, Livia Sanz-Sánchez, Jorge Baladrón Zorita, Carlos Iñiguez Romo, Andrés Muñoz García, Antonio Jesús Vilalta, Victoria Ojeda, Soledad Veiga Fernández, Gabriela Córdoba Soriano, Juan Gabriel Cepas, Pedro Sandín Rollán, Miriam Ríos, Xacobe Flores Palma-Carbajal, Ricardo Martín Reyes, Roberto Romaguera, Rafael Avanzas, Pablo Franco-Peláez, Juan A Martín Moreiras, Javier Gonzalez Juanatey, José Ramón Tirado, Gabriela Calle, German Díez, José Luis Santos-Martínez, Sandra Domínguez Erquicia, Pablo García, Erika Muños Fernandez-Nofrerias, Eduard López País, Javier Gonzalo, Nieves Barri, Alejandro Gutierrez Asmarats, Lluis López Pérez, Manuel Domínguez Rodríguez, Luis Manuel Cobo, Marta González Bermúdez, Inmaculada García Álvarez, Ana García Pavía, Pablo Fuster, Valentín Ibáñez, Borja Raposeiras-Roubín, Sergio
author	Bonanad-Lozano, Clara
author_facet	Bonanad-Lozano, Clara García Blas, Sergio Amat-Santos, Ignacio Gonzalez-Manzanares, Rafael Sanchís, Juan López Otero, Diego Nombela Franco, Luis Gheorge, Livia Sanz-Sánchez, Jorge Baladrón Zorita, Carlos Iñiguez Romo, Andrés Muñoz García, Antonio Jesús Vilalta, Victoria Ojeda, Soledad Veiga Fernández, Gabriela Córdoba Soriano, Juan Gabriel Cepas, Pedro Sandín Rollán, Miriam Ríos, Xacobe Flores Palma-Carbajal, Ricardo Martín Reyes, Roberto Romaguera, Rafael Avanzas, Pablo Franco-Peláez, Juan A Martín Moreiras, Javier Gonzalez Juanatey, José Ramón Tirado, Gabriela Calle, German Díez, José Luis Santos-Martínez, Sandra Domínguez Erquicia, Pablo García, Erika Muños Fernandez-Nofrerias, Eduard López País, Javier Gonzalo, Nieves Barri, Alejandro Gutierrez Asmarats, Lluis López Pérez, Manuel Domínguez Rodríguez, Luis Manuel Cobo, Marta González Bermúdez, Inmaculada García Álvarez, Ana García Pavía, Pablo Fuster, Valentín Ibáñez, Borja Raposeiras-Roubín, Sergio
author_role	author
author2	García Blas, Sergio Amat-Santos, Ignacio Gonzalez-Manzanares, Rafael Sanchís, Juan López Otero, Diego Nombela Franco, Luis Gheorge, Livia Sanz-Sánchez, Jorge Baladrón Zorita, Carlos Iñiguez Romo, Andrés Muñoz García, Antonio Jesús Vilalta, Victoria Ojeda, Soledad Veiga Fernández, Gabriela Córdoba Soriano, Juan Gabriel Cepas, Pedro Sandín Rollán, Miriam Ríos, Xacobe Flores Palma-Carbajal, Ricardo Martín Reyes, Roberto Romaguera, Rafael Avanzas, Pablo Franco-Peláez, Juan A Martín Moreiras, Javier Gonzalez Juanatey, José Ramón Tirado, Gabriela Calle, German Díez, José Luis Santos-Martínez, Sandra Domínguez Erquicia, Pablo García, Erika Muños Fernandez-Nofrerias, Eduard López País, Javier Gonzalo, Nieves Barri, Alejandro Gutierrez Asmarats, Lluis López Pérez, Manuel Domínguez Rodríguez, Luis Manuel Cobo, Marta González Bermúdez, Inmaculada García Álvarez, Ana García Pavía, Pablo Fuster, Valentín Ibáñez, Borja Raposeiras-Roubín, Sergio
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv	NYHA functional class aortic stenosis dapagliflozin quality of life transcatheter aortic valve implantation (TAVI)
topic	NYHA functional class aortic stenosis dapagliflozin quality of life transcatheter aortic valve implantation (TAVI)
description	Patients with aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) experience a great improvement in health status. Dapagliflozin has been shown to reduce death and heart failure (HF) in these patients. However, the impact of dapagliflozin on improving health status after TAVI is unknown. In this prespecified analysis of the DapaTAVI (Dapagliflozin After Transcatheter Aortic Valve Implantation) trial, we examined the effects of dapagliflozin on health status by using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The DapaTAVI trial randomized patients undergoing TAVI to receive or not receive dapagliflozin. We assessed the change in KCCQ score from baseline to 3 and 12 months by using an ordinal logistic regression model. Additionally, we analyzed the effect of dapagliflozin on the composite of death or worsening HF by baseline KCCQ score. A total of 964 patients had baseline KCCQ scores (mean 39.5 ± 22.2). Patients in both arms of the study exhibited improvements in KCCQ score, without significant differences between groups in the change in KCCQ score at 3 or 12 months (3-month OR for improvement: 0.96; 95% CI: 0.72-1.26; P = 0.745; 12-month OR: 1.03; 95% CI: 0.83-1.27; P = 0.819). At 12 months, similar proportions of patients in the dapagliflozin and control groups showed clinically meaningful improvements, with 43.4% vs 45.4%, respectively, improving by >50 points. The clinical benefits of dapagliflozin after TAVI appeared to be similar across the full range of baseline KCCQ scores. TAVI was associated with a substantial improvement in KCCQ scores. However, the addition of dapagliflozin following the procedure did not confer an additional benefit in health status compared with standard care. (Dapagliflozin After Transcatheter Aortic Valve Implantation [DapaTAVI]; NCT04696185).
publishDate	2025
dc.date.none.fl_str_mv	2025 2025-12-16 2025 2025-10-14 2025 2025-10-14
dc.type.none.fl_str_mv	research article http://purl.org/coar/resource_type/c_2df8fbb1 AM http://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/20.500.12105/27044
url	https://hdl.handle.net/20.500.12105/27044
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	ELSEVIER
publisher.none.fl_str_mv	ELSEVIER
dc.source.none.fl_str_mv	reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII)
instname_str	Instituto de Salud Carlos III (ISCIII)
reponame_str	Repisalud
collection	Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869404303783886848
score	15,81155

Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.

Similares en LA Referencia